Search cutoffs
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Search companies, layoffs, filings, signals, and visa data
Current report (Form 8-K) · Jun 11, 2026 · Other material event · Financial statements
Silence Therapeutics plc
5
Other material event
Jun 11, 2026
| Form type | Current report (Form 8-K) |
| Event summary | Other material event · Financial statements |
| Primary topic | Other material event |
| About this form | Public companies file this within four business days when something important happens that investors should know about, before the next quarterly report. |
| Why this was filed | Silence Therapeutics plc filed this to release information to investors under Regulation FD, usually a press release, conference presentation, or other event the company considers important. 1 Silence Therapeutics Highlights Follow-Up Data at EHA 2026 Demonstrating Durable Efficacy and Potential Best-in-Class Profile for Divesiran in Polycythemia Vera New analyses from the Phase 1 SANRECO study demonstrate potential improvements in PV symptoms and quality-of-life Follow-up data show substantial reductions in phlebotomy use persisting after final… |
| Labor angle | Watch for Item 2.05 (restructuring or severance), Item 5.02 (leadership changes), and Item 1.01 (major contracts that can precede workforce shifts). |
| Period of report | Jun 11, 2026 |
| Accession number | 0001193125-26-266705 |
| Reported items | Other events the company considers material, Financial statements and exhibits See Analysis tab for workforce implications |
